lung adenocarcinoma
Conditions
Interventions
intervention:Furmonertinib
Sponsors
Department of thoracic surgery, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1- Age range: 18-70 years, both males and females are eligible. 2- Locally advanced lung adenocarcinoma confirmed by pathology, clinically staged as T3-4N0-2M0. 3- Positive for EGFR sensitive gene mutations, specifically EGFR 19 deletion mutation and EGFR 21 L858R mutation. 4- No previous exposure to radiotherapy or chemotherapy. 5- ECOG PS (Eastern Cooperative Oncology Group Performance Status): 0-1 points. 6- Subjects must voluntarily participate in this study, sign an informed consent form, demonstrate good compliance, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1-History of malignancy. 2-Presence of single or multiple distant metastases. 3-Poorly controlled heart diseases or symptoms, such as: a. heart failure(NYHA class 2 or higher). b. Unstable angina. c. Myocardial infarction within the past year. d. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention. 4-Severe COPD (Chronic Obstructive Pulmonary Disease), FEV1 (Forced Expiratory Volume in one second) < 0.8L, FEV1% < 50%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 rate;MPR;mPFS; | — |
Countries
China
Contacts
Public ContactBo Ai
Department of thoracic surgery, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
Outcome results
None listed